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Background: Long-term data from patients with tuberous sclerosis complex (TSC)-associated renal
angiomyolipoma (angiomyolipoma) are limited.
Study Design: Retrospective observational study.
Setting & Participants: Adult patients with TSC treated at the University Medical Center Utrecht (the
Netherlands) from January 1990 through April 2012.
Predictors: Patient age and angiomyolipoma stage, based on computed tomography lesion count, size, and
impact on renal anatomy, with higher stage representing higher angiomyolipoma burden. Patients in stages 3
or higher were considered at high risk for hemorrhage and candidates for selective arterial embolization.
Outcomes: Kidney-related outcomes included hypertension, anemia, decreased kidney function, dialysis,
kidney transplantation, nephrectomy, kidney-related blood transfusions, and mortality. Observed mortality was
compared to the Dutch National Bureau of Statistics using standardized mortality ratio.
Results: Median follow-up was 15.8 years, of which staging was available for 5.4 years. Of 351 patients with
TSC, 244 (69.5%) had confirmed angiomyolipoma; 144 (59.0%) reached stage 3 or higher. Age and
angiomyolipoma stage were positively correlated: median age in the none-detected stage was 36.8 years,
increasing to 43.6 years for stage 6. Embolization was performed in 117 patients; 57 had 2 or more
embolization procedures. Higher stage was associated with hypertension, anemia, decreased kidney function,
and transfusion. Hypertension, anemia, and decreased kidney function were more common in patients who
underwent selective arterial embolization. 7 patients required dialysis, 7 received a kidney transplant, and 16
underwent nephrectomy. 29 deaths were recorded, most commonly related to renal complications (n 5 9
[31%]). Mortality was significantly higher in the study cohort versus the general population (standardized
mortality ratio, 4.8; 95% CI, 3.4-6.9).
Limitations: Duration of follow-up with staging was too short to observe stage progression in most patients.
Conclusions: Despite the use of preventive selective arterial embolization, patients with TSC exhibit
clinically significant kidney disease and excess mortality, largely because of kidney-related complications.
Am J Kidney Dis. 66(4):638-645. ª 2015 The Authors. Published by Elsevier Inc. on behalf of the National
Kidney Foundation, Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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hamartoma; angiomyolipoma staging criteria; angiomyolipoma progression; mortality; morbidity.Tuberous sclerosis complex (TSC) is a multisystemdisorder characterized by growth of nonma-
lignant tumors (hamartomas) in various organs
throughout the body, including the brain, kidney,
lungs, and skin.1,2 Most patients with TSC have mu-
tations in the TSC1 or TSC2 genes, which encode the
proteins hamartin and tuberin, respectively.3 Together,
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Renal Angiomyolipoma in the Netherlandscomposed of abnormal blood vessels, immature
smooth muscle cells, and adipose tissue, occur in up to
75% of patients with TSC and are typically multiple in
number and located bilaterally.5 In addition to renal
angiomyolipomas, other common renal manifestations
of TSC include epithelial cysts (45%) and renal cell
carcinoma (2%-3%).5
Renal angiomyolipoma is associated with signiﬁ-
cant morbidity and mortality. Adverse outcomes
associated with renal angiomyolipoma can be acute,
resulting from the hemorrhage of a lesion, or long
term because progressive loss of normal renal pa-
renchyma decreases kidney function and can lead to
kidney failure.1,7-9 Retroperitoneal hemorrhage, also
referred to as Wunderlich syndrome, is an acute
possibly severe event that can result in death.7 A
medical chart review revealed kidney disease in the
form of angiomyolipomas, cysts, or both as the most
common cause of death in patients with TSC.10
The vasculature of renal angiomyolipoma is char-
acterized by thick-walled blood vessels that lack
normal elastin, making them prone to rupture.11
Yamakado et al12 reported that aneurysm size was
the most signiﬁcant predictor of hemorrhage and that
angiomyolipoma size and aneurysm size were posi-
tively correlated. Similarly, a UK renal registry
analysis showed increased risk for hemorrhage in le-
sions demonstrating serial growth.13
Renal angiomyolipoma treatment goals focus on
preventing acute events, preserving renal parenchyma,
and maintaining long-term kidney function. At the time
of this study, approved treatment options in the
Netherlands included observation, nephron-sparing
procedures (partial nephrectomy, cryotherapy, and
radiofrequency ablation), and selective arterial emboli-
zation. Historically, embolization was reserved for
symptomatic cases in which the angiomyolipoma
caused bleeding.14-16 In the early 2000s, practitioners
began to use embolization on an elective basis in patients
with large growing angiomyolipomas to prevent hem-
orrhage and preserve kidney function. This practice was
added to the Dutch treatment guidelines in 2006.17
Although a number of studies describe the patho-
physiology, epidemiology, and treatment of renalTable 1. Renal Angiomyolipoma Staging Criteria P
Stage No. of Angiomyolipoma
None detecteda None $ 1 cm in longest diameter
1 #5
2 .5
3 #5
4 .5
5 .5
6 .5
aAngiomyolipoma not detectable or lesions , 1 cm unidentifiable
Am J Kidney Dis. 2015;66(4):638-645angiomyolipomas in patients with TSC, most have
small patient samples and short periods of follow-up.
The literature documenting long-term follow-up after
elective embolization is limited. Consequently, most
studies focus on reducing the number of acute events
and are not able to report on long-term outcomes,
including kidney function.This studywas undertaken to
evaluate renal angiomyolipoma characteristics, treat-
ment patterns, and associated long-term outcomes in a
large cohort of patients with TSC in the Netherlands.
METHODS
Participants
Inclusion criteria for this retrospective analysis were diagnosis of
TSC according to the modiﬁed Gomez criteria (2 major or 1 major
and 2 minor criteria)18 and aged 18 years or older. From January
1990 through April 2012, patients were treated at the University
Medical Center Utrecht (UMCU), where elective embolization is
used in patients with TSC with at least one renal angiomyolipoma$
3.5 cm (in longest diameter) that shows serial growth.
Patients or family caregivers could opt out of participation; as a
result, data from 2 patients were omitted. This study was approved
by UMCU’s Institutional Review Board.
Data Sources and Measurement
Data were extracted from UMCU’s electronic medical records
system and combined with information from older paper-based
records and medical charts. Computed tomographic (CT) scans
were available from 2000 onward and were generally performed
every 2 to 3 years as part of routine follow-up. (Magnetic reso-
nance imaging was not widely available.) When possible, radio-
logic reports were used when original scans were unavailable.
Angiomyolipoma and subependymal giant cell astrocytoma were
identiﬁed by CT scan, epilepsy was measured by electroenceph-
alography, and other manifestations were determined by clinical
examination and history taking. Observations of the treating
physician were used to determine the presence of skin lesions and
assess cognitive function. Kidney function was measured by
calculating estimated glomerular ﬁltration rate using the CKD-EPI
(Chronic Kidney Disease Epidemiology Collaboration) creatinine
equation.19 For this analysis, patients with estimated glomerular
ﬁltration rates , 60 mL/min/1.73 m2 were considered to have
decreased kidney function. Renal angiomyolipoma staging criteria
developed at UMCU were used as part of the clinical assessment.
The criteria (Table 1) are based on 3 factors: number of angio-
myolipomas (both kidneys), size of angiomyolipomas, and gross
radiologic anatomy of the kidney. Because angiomyolipomas can
distort the gross appearance and architecture of the kidney, in-
spection of kidney anatomy is helpful in ascertaining the extent of
disease. Embolization was performed using a combination ofroposed by University Medical Center Utrecht
Angiomyolipoma Size Description of Kidney Anatomy
— Normal
,3.5 cm Normal
,3.5 cm Normal
At least 1 $3.5 cm Kidney intact
1-4 $3.5 cm Kidney intact
$5 $3.5 cm Kidney recognizable
At least 1 $5.0 cm Kidney not recognizable
as angiomyolipoma.
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Table 2. Baseline Patient Demographics and Clinical
Characteristics for All Patients, and Stratified by Presence of
Angiomyolipoma During Follow-up
All
(N 5 351)
AML in F/U
(n 5 244)
No AML in F/U
(n 5 107)
Age at end of F/U, y 39.8 (18-89) 40.3 (18-79) 35.5 (18-89)
Sex
Male 176 (50.1) 127 (52.0) 49 (45.8)
Female 175 (49.8) 117 (48.0) 58 (54.2)
Race
White 345 (98.3) 239 (98.0) 106 (99.1)
Other 6 (1.7) 5 (2.0) 1 (0.9)
Diagnosis of TSC
Confirmed 342 (97.4) 242 (99.2) 100 (93.5)
Suspected 9 (2.6) 2 (0.8) 7 (6.5)
Manifestations
present
SEGA 81 (23.1) 66 (27.0) 15 (14.0)
SEN 225 (64.1) 169 (69.3) 56 (52.3)
Rhabdomyomas 36 (10.3) 28 (11.5) 8 (7.5)
Lipomas 108 (30.8) 84 (34.4) 24 (22.4)
Angiofibromas 249 (70.9) 178 (73.0) 71 (66.4)
Hypomelanotic
macules
138 (39.3) 87 (35.7) 51 (47.7)
LAM 40 (11.4) 35 (14.3) 5 (4.7)
Epilepsy 273 (77.8) 202 (82.8) 71 (66.4)
Autism/autism
spectrum
disorder
58 (16.5) 45 (18.4) 13 (12.1)
Low/very low
cognitive
function
195 (55.6) 155 (63.5) 40 (37.4)
Note: Values for categorical variables are given as number
(percentage); for continuous variables, as median (range).
Abbreviations: AML, angiomyolipoma; F/U, follow-up; LAM,
lymphangioleiomyomatosis; SEGA, subependymal giant cell
astrocytoma; SEN, subependymal nodule; TSC, tuberous scle-
rosis complex.
Eijkemans et altrisacryl gelatin microspheres (Embosphere; Merit Medical) and a
mixture of polyvinyl alcohol particles, with no coiling. Dexa-
methasone and acetaminophen were used to avoid postemboliza-
tion syndrome and manage pain.
Statistical Methods
Median age at ﬁrst occurrence of angiomyolipoma and age at
which renal angiomyolipomas became high risk for hemorrhage
(renal angiomyolipoma stage $ 3, per Table 1) were estimated
using parametric survival models with age from birth as the time
axis. Weibull and log-normal distributions were ﬁtted and the best-
ﬁtting model, based on the deviance, was chosen. Censoring was
used to address: (1) patients who already had angiomyolipomas at
the time of ﬁrst observation (left censoring), (2) patients who were
angiomyolipoma free at last follow-up (right censoring), and (3)
patients who developed angiomyolipomas between 2 follow-up
visits (interval censoring). These censoring patterns necessitated
the use of a parametric model.
Descriptive statistics (number, percentage, mean, and standard
deviation) were calculated for the highest observed angiomyoli-
poma stage and kidney-related outcomes (hypertension [systolic
blood pressure . 140 mm Hg and/or diastolic blood pressure .
90 mm Hg], anemia [hemoglobin level , 12.5 g/dL in women
or,13.5 g/dL in men], decreased kidney function, dialysis, kidney
transplantation, nephrectomy, kidney-related blood transfusions,
and mortality). Correlations between the highest observed stage and
kidney-related outcomes were analyzed by cross-tabulation and c2
tests for trend. Additionally, the correlation between hemoglobin
level and log(estimated glomerular ﬁltration rate) was assessed by
Pearson correlation coefﬁcient to better understand the underlying
cause of anemia. The subgroup of patients with available CT scans
was used for select analyses. In cases in which CT scans were not
discernible, not taken, or otherwise unavailable, patients could not
be categorized into an angiomyolipoma stage and were omitted
from longitudinal models.
Descriptive statistics were used to report associations between
the number of embolizations and kidney-related outcomes and
mortality. Because 9 outcomes were analyzed separately, Bon-
ferroni correction for multiple testing was applied to P values (ie,
the critical P for signiﬁcance was 0.05/9 5 0.0056).
Time-dependent Cox proportional hazards models were used to
analyze outcomes associated with elective embolization and
nonelective embolization (which included cases in which it was
not possible to conﬁrm the embolization was done on an elective
basis). The Cox model compares in a time-dependent fashion the
risk of kidney-related outcomes and death from the time of the
embolization procedure with patients of the same age who had not
undergone embolization. Embolizations were classiﬁed as either
elective or nonelective based on information in the patient’s re-
cord. The ﬁrst occurrence of each type of embolization was
analyzed with adjustment for the highest observed angiomyoli-
poma stage. The time axis was age, with left truncation at the age
of entry into the study and right-censoring for patients who had not
reached the event of interest at last follow-up. Using this approach,
the confounding effect of age was automatically accounted for.
Overall mortality was analyzed using the Kaplan-Meier method
and compared with the expected survival curve based on age- and
sex-matched mortality records for the population at risk, at each
follow-up, from the Dutch National Bureau of Statistics. Differ-
ences between observed and expected survival curves were
analyzed using the standardized mortality ratio with 95% conﬁ-
dence interval (CI) and P value based on the Poisson model.20 The
observed number of deaths in each combination of age, sex, and
calendar year was used as the dependent variable, and the expected
number of deaths for the same age-sex–calendar year combina-
tions was used as an offset in the Poisson model. Additionally, a
Cox regression analysis was used to explore the relationship640between cognitive status and overall mortality. All analyses were
performed using R statistical software package, version 3.02 (R
Foundation for Statistical Computing). Standardized mortality ra-
tio analysis was done with the R package survexp.fr.
RESULTS
Baseline Demographics
A total of 351 patients with TSC were identiﬁed at
UMCU from January 1990 through April 2012.
Baseline patient demographics and clinical character-
istics are shown overall and separately for patients
with and without renal angiomyolipomas (Table 2).
Proportions of female and male patients were equal,
and most were of European ancestry. Prevalent TSC
manifestations were epilepsy, renal angiomyolipomas,
angioﬁbromas, and subependymal nodules. More than
half the patients had low to very low cognitive func-
tion (required semiconstant or constant oversight from
a caregiver in a protective setting). Information was
sufﬁcient in 332 of 351 (94.6%) patients to assign aAm J Kidney Dis. 2015;66(4):638-645
Renal Angiomyolipoma in the Netherlandsrenal angiomyolipoma stage (including 88 with “none
detected”). Nineteen (7%) patients had evidence of
angiomyolipoma but could not be staged because of
missing or inadequate radiologic imaging. These pa-
tients were included in the none-detected group for
analyses. Sex distribution of the 244 patients with
angiomyolipomas (127 men and 117 women) was si-
milar to patients without angiomyolipomas (P5 0.3).
Mean age at the end of follow-up was 39.8 (range, 18-
89) years. Overall mean duration of follow-up was 15.8
years. However, the mean duration of follow-up for
which CT scans or reports were available was 5.4
years. Consequently, in most patients, changes of renal
angiomyolipomas from one stage to another were not
commonly observed.
Renal Angiomyolipoma Stage and Disease
Progression
Of 244 patients with a renal angiomyolipoma, 144
(59%) had a highest observed stage of 3 or higher, at
which point patients are considered at high risk for
hemorrhage and are candidates for elective emboli-
zation per the UCMU treatment protocol. Nearly half
the high-risk patients were women.
Age and renal angiomyolipoma stage were posi-
tively correlated: median age in the none-detected
stage was 36.8 years, increasing to 43.6 years in
stage 6. The Weibull model best ﬁt this study’s age
versus angiomyolipoma stage distribution and was
used to estimate median age at ﬁrst renal angiomyo-
lipoma occurrence, which was 8.6 (95% CI, 2.1-15.1)
years. The median age at which renal angiomyolipo-
mas became high risk for hemorrhage (stage $ 3),
also estimated using a Weibull model, was 46.0 (95%
CI, 37.9-54.0) years (Fig 1).
Embolization Proﬁle by Highest Renal
Angiomyolipoma Stage
A total of 117 patients had one or more emboliza-
tion; 57 had at least 2. The number of embolization806040200
0.0
0.2
0.4
0.6
0.8
1.0
Pr
op
or
tio
n 
w
ith
 a
ng
io
m
yo
lip
om
a
si
ze
 <
 3
.5
 c
m
 
Age (years)
Estimated Weibull Curve 
95% CI
Figure 1. Time-to-event model of age of becoming high risk
for hemorrhage (angiomyolipoma size $ 3.5 cm). Estimated
Weibull curve (solid), with 95% confidence interval (CI; dotted).
The median age is the age at which the solid curve passes
through the 0.5 level.
Am J Kidney Dis. 2015;66(4):638-645procedures per patient increased accordingly with
angiomyolipoma stage for patients in stages 3 to 6.
Patients in stages 0 to 2 typically were not treated with
elective embolization. The mean number of emboli-
zations per patient in stage 3 was 0.85, increasing to
2.06 in stage 6 (Table 3). Mean patient age at the time
of the ﬁrst embolization did not correlate with
increasing angiomyolipoma stage. In general, the
embolization rate (number of embolizations per year)
increased as renal angiomyolipoma stage increased.
For stage 3, the embolization rate was 0.09, compared
with 0.14 for stage 6 (P 5 0.03). Based on these
embolization rates, patients in stage 3 require embo-
lization approximately every 11 years, whereas pa-
tients in stage 6 require embolization every 7 years.
Kidney-Related Outcomes
The occurrence of hypertension, anemia, decreased
kidney function, and blood transfusion corresponded
with increasing renal angiomyolipoma stage (P for
trend , 0.001; Table 4). Anemia was a common
occurrence overall (60.7%). A positive correlation
between anemia (lowest hemoglobin level) and
decreased kidney function was found (r 5 0.31;
P , 0.001). Seven patients required kidney dialysis, 7
underwent kidney transplantation, and 16 underwent
nephrectomy. Of the 7 patients who underwent kidney
transplantation, some never required dialysis.
Bleeding complications from nephrectomy were not
the cause of dialysis or transplantation in any patient in
this study. The small number of transplantation and
dialysis cases in the none-detected and stage-2 groups
were likely the result of numerous relatively small
(,1 cm) angiomyolipomas in both kidneys. In addi-
tion, due to the unknown angiomyolipoma stage of the
19 patients with missing or inadequate imaging who
were classiﬁed in the none-detected angiomyolipoma
group, we performed a sensitivity analysis to test
whether removing these patients modiﬁed the results.
The signiﬁcance of the results was not affected.
Kidney outcomes are reported by number of
embolization procedures in Table 5. Anemia was
common regardless of the number of embolizations
and occurred in 49.6%, 76.7%, 87.2%, and 94.4% of
patients who had undergone 0, 1, 2, or 3 or more
procedures, respectively. Hypertension and decreased
kidney function were substantially more prevalent in
patients who underwent embolization versus those
who did not. Half (50.0%) the patients who underwent
3 or more embolizations had decreased kidney func-
tion. The occurrence of postembolization syndrome
and need for a kidney transplant did not correspond
with an increase in embolization procedures.
Risk for kidney outcomes is reported based on
whether the ﬁrst embolization was elective or non-
elective (Table 6). When patients underwent elective641
Table 3. Embolization Profile by Highest Angiomyolipoma Stage Attained During Follow-Up
Highest
Angiomyolipoma Stage No. of Patients
Embolizations
Per Patient
Age at First
Embolization, y Embolization Ratea
Unknownb 19 (5.4) NA NA NA
None detectedc 88 (25.0) NA NA NA
1 48 (13.7) NA NA NA
2 52 (14.8) NA NA NA
3 13 (3.7) 0.85 6 0.90 41.7 6 16.7 0.09 6 0.10
4 69 (19.7) 1.06 6 1.03 32.8 6 11 0.08 6 0.13
5 28 (8.0) 1.32 6 1.12 39.4 6 14.5 0.11 6 0.11
6 34 (9.7) 2.06 6 1.89 35.2 6 12.4 0.14 6 0.15
Note: Values are given as number (percentage) or mean 6 standard deviation.
Abbreviation: NA, not applicable.
aNumber of embolizations per year.
bPatients had angiomyolipomas but could not be classified due to a lack of computed tomographic scans.
cAngiomyolipoma not detectable or lesions , 1 cm unidentifiable as angiomyolipoma.
Eijkemans et alembolization (compared with those who did not un-
dergo embolization), the hazard ratio (HR) for the ﬁrst
occurrence of hypertension was 3.04 (P, 0.001), and
for theﬁrst occurrence of anemiawas 3.92 (P , 0.001).
When patients underwent nonelective embolization
(compared with those who did not undergo emboli-
zation), the HR for the ﬁrst occurrence of anemia
was 3.83 (P , 0.001), and for the ﬁrst occurrence
of decreased kidney function was 2.88 (P 5 0.005).
Mortality Analysis
Twenty-nine deaths were recorded during the
observation period. Leading causes of death were renal
complications (n 5 9 [31%]), cancer (n 5 5 [17%]),Table 4. Observed Frequencies of Kidney-Related Outcom
Angiomyolipoma HTNa,b Anemiab,c
Decreased
Kidney
Functionb,d Dialysis
Unknown,g n5 19 3 (16) 8 (42) 3 (16) 1 (5)
None detected,h
n5 88
10 (11) 34 (39) 4 (5) 1 (1)
Stage
1, n 5 48 8 (17) 27 (56) 5 (10) 0 (0)
2, n 5 52 10 (19) 35 (67) 7 (14) 1 (2)
3, n 5 13 6 (46) 6 (46) 2 (15) 0 (0)
4, n 5 69 21 (30) 55 (80) 12 (17) 1 (1)
5, n 5 28 13 (46) 19 (68) 9 (32) 1 (4)
6, n 5 34 20 (59) 29 (85) 16 (47) 2 (6)
Total, n 5 351 91 (25.9) 213 (60.7) 58 (16.5) 7 (2.0)
Note: Values are given as number (percentage). All percentages
Abbreviations: HTN, hypertension; Tx, transplantation.
aDefined as systolic blood pressure . 140 mm Hg and/or diastolic
bP , 0.001.
cDefined as hemoglobin , 12.5 g/dL (women) or ,13.5 g/dL (men
dDefined as estimated glomerular filtration rate , 60 mL/min/1.73
eKidney related.
fP, 0.05 tests for trend.
gPatients had angiomyolipomas but could not be classified due to
hAngiomyolipoma not detectable or lesions , 1 cm unidentifiable
642and epilepsy (n 5 3 [10%]). Other causes were un-
known or occurred in 2 or fewer patients. Renal
complications leading to death included reduced kid-
ney function in patients for whom hemodialysis was
not appropriate (n 5 4), complications following
embolization (n 5 3), angiomyolipoma hemorrhage
(n 5 1), and septicemia after spontaneous abscess in a
renal angiomyolipoma (n 5 1). One patient died of an
infection after kidney transplantation. Of patients who
died from renal complications, 7 had low or very low
cognitive function. Overall, patients with low or very
low cognitive function had an increased risk of all-
cause mortality (HR, 2.97; P 5 0.02, adjusted for
angiomyolipomas stage).es According to Highest Renal Angiomyolipoma Stage
Kidney Tx Nephrectomy Transfusionb,e
Death
All
Cause
Renal
Causef
2 (11) 1 (5) 1 (5) 2 (11) 0 (0)
1 (1) 2 (2) 1 (1) 2 (2) 1 (1)
0 (0) 1 (2) 3 (6) 6 (13) 1 (2)
1 (2) 3 (6) 2 (4) 5 (10) 0 (0)
0 (0) 1 (8) 0 (0) 0 (0) 0 (0)
0 (0) 2 (3) 3 (4) 8 (12) 3 (4)
1 (4) 2 (7) 2 (7) 0 (0) 0 (0)
2 (6) 4 (12) 10 (29) 6 (18) 4 (12)
7 (2.0) 16 (4.6) 22 (6.3) 29 (8.3) 9 (2.6)
are calculated within their respective row.
blood pressure . 90 mm Hg.
).
m2.
a lack of computed tomographic scans.
as angiomyolipoma.
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Table 5. Observed Frequencies of Kidney-Related Outcomes, Postembolization Syndrome, and Mortality According to Number of
Renal Embolizations
Embolization
Procedures HTNa Anemiab
Decreased
Kidney
Functionc Dialysis Kidney Tx Nephrectomy
Postembolization
Syndrome
Death
All Cause Renal Cause
None, n 5 234 44 (18.8) 116 (49.6) 24 (10.2) 4 (1.7) 5 (2.1) 9 (3.8) — 18 (7.7) 3 (1.3)
1, n5 60 23 (38) 46 (77) 17 (28) 0 (0) 1 (2) 3 (5) 12 (12) 5 (8) 2 (3)
2, n5 39 17 (44) 34 (87) 8 (21) 0 (0) 1 (3) 1 (3) 4 (8) 4 (10) 2 (5)
$3, n 5 18 7 (39) 17 (94) 9 (50) 3 (17) 0 (0) 3 (17) 4 (11) 2 (11) 2 (11)
Total, n 5 351 91 (25.9) 213 (60.7) 58 (16.5) 7 (2.0) 7 (2.0) 16 (4.6) 20 (10.5) 29 (8.3) 9 (2.6)
Note: Values are given as number (percentage). All percentages are calculated within their respective row.
Abbreviations: HTN, hypertension; Tx, transplantation.
aDefined as systolic blood pressure . 140 mm Hg and/or diastolic blood pressure . 90 mm Hg.
bDefined as hemoglobin , 12.5 g/dL (women) or ,13.5 g/dL (men).
cDefined as estimated glomerular filtration rate , 60 mL/min/1.73 m2.
Renal Angiomyolipoma in the NetherlandsThe effect of elective and nonelective embolizations
on risk for all-cause and kidney-related mortality were
also assessed (Table 6). When patients underwent
elective embolization, the HR for all-cause mortality
compared with patients of the same age who did not
undergo embolization was 0.49 (P5 0.4), and the HR
for death as a result of renal complication was 0.53
(P5 0.4). When patients underwent nonelective
embolization, HRs for all-cause mortality and death as
a result of renal complications were 5.4 (P5 0.007)
and 4.67 (P5 0.02), respectively (Table 6). Although
these values are clinically meaningful, they were not
statistically signiﬁcant after Bonferroni correction for
multiple testing.
The mortality rate in patients with TSC was signif-
icantly higher than in the Dutch general population
(standardized mortality ratio, 4.8; 95% CI, 3.4-6.9;
Fig 2), indicating that the 29 deaths observed in thisTable 6. Effect of Elective and Nonelective Embolizations
Outcome
Electivea
HR (95% CI)
First occurrence of
Hypertensionb 3.04 (1.71-5.41)c
Anemiad 3.92 (2.29-6.73)c
Decreased kidney functione 1.41 (0.68-2.92)
Dialysis initiation 2.01 (0.14-27.99)
First nephrectomy 0.38 (0.05-3.13)
Death
All cause 0.49 (0.11-2.26)
Renal complications 0.53 (0.11-2.47)
Note: Unknown refers to before 2000.
Abbreviations: CI, confidence interval; HR, hazard ratio.
aEffects on kidney-related outcomes of elective and nonelective e
the embolization was performed onward.
bDefined as systolic blood pressure . 140 mm Hg and/or diastolic
cSignificant after Bonferroni correction for multiple testing.
dDefined as hemoglobin , 12.5 g/dL (women) or ,13.5 g/dL (men
eDefined as estimated glomerular filtration rate , 60 mL/min/1.73
Am J Kidney Dis. 2015;66(4):638-645study are almost 5 times higher than deaths of an age-
and sex-matched group randomly selected from the
Dutch general population over the same period.
DISCUSSION
Nearly three-quarters of the patients with TSC in
this study had renal angiomyolipomas, and more
than half were considered at high risk for hemor-
rhage based on the staging criteria described here.
Patients with renal angiomyolipomas at higher stages
were found to be at increased risk for many of the
adverse kidney outcomes that were measured.
Further, angiomyolipoma stage correlated with age,
number of embolization procedures, and number of
embolizations per year. These data suggest that
angiomyolipoma staging criteria could serve as a
diagnostic tool for evaluating disease burden at
initial assessment and provide a scale for clinicianson Unadjusted Kidney-Related Outcomes and Mortality
Nonelective/Unknowna
P HR (95% CI) P
,0.001c 0.43 (0.17-1.08) 0.07
,0.001c 3.83 (2.15-6.80)c ,0.001c
0.4 2.88 (1.38-6.02)c 0.005c
0.6 10.47 (0.91-121.18) 0.06
0.4 1.95 (0.47-8.00) 0.4
0.4 5.40 (1.59-18.40) 0.007
0.4 4.67 (1.30-16.78) 0.02
mbolization are time-dependent variables, from the age at which
blood pressure . 90 mm Hg.
).
m2.
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Figure 2. Survival curve of patients with angiomyolipomas
compared with that expected from the general population in
the Netherlands.
Eijkemans et alfor tracking angiomyolipoma progression. Formal
validation of the staging criteria is recommended so
it can be used broadly in clinical practice.
Although the frequencies of most clinical features
suggestive of or related to kidney disease (including
hypertension, anemia, decreased kidney function, and
blood transfusion) correspond with higher angio-
myolipoma stage, anemia was common at all stages.
One possible explanation for the high rate of anemia
is that renal angiomyolipomas, irrespective of size,
reduce the proportion of functional renal parenchyma,
which ultimately affects erythropoietin secretion from
peritubular interstitial cells in the renal cortex and
outer medulla of the kidney.21 A connection between
anemia and renal tissue injury has previously been
reported in acute and long-term settings.21 Therefore,
anemia may be an early surrogate marker for kidney
damage in patients with TSC.
At the time of this study, embolization was the
standard of care in the Netherlands for symptomatic
(bleeding) angiomyolipomas and asymptomatic (non-
hemorrhagic) large angiomyolipomas exhibiting serial
growth. In symptomatic angiomyolipomas, emboliza-
tion aims to stop bleeding by occluding aneurysmal
blood vessels. Embolization was also believed to reduce
angiomyolipoma size and potentially prevent additional
growth due to the effect on afferent vessels, all while
preserving kidney function. For these reasons, and the
ability to preemptively reduce the risk for hemorrhage
(when able to identify the aneurysm), embolization was
considered a viable elective treatment approach.
One aim of this study was to assess the impact of
elective embolization on patient outcomes in order to
help clinicians evaluate treatment options. The number
of acute clinically dangerous hemorrhages was low in
our study group, likely as a result of the use of elective
embolization. However, we observed that embolization644was not always effective in cutting off the blood supply
to the lesion, necessitating additional interventions.
Given the number of kidney lesions often present in
patients with TSC, it is difﬁcult to differentiate between
recurrence and growth of an adjacent angiomyoli-
poma.22 Nevertheless, the embolization rate reported
here suggests that patients with large growing asymp-
tomatic angiomyolipomas will require an embolization
every 7 to 11 years, something that may contribute to
accelerated decline in kidney function.
With respect to kidney-related outcomes, we found
similar adverse outcomes associated with elective and
nonelective embolization. Regardless of the circum-
stances leading to embolization (elective or nonelective),
patients who underwent the procedure were at a signiﬁ-
cantly higher risk for anemia. However, compared with
having no embolization, the risk for developing hyper-
tensionwas3-foldgreater followinganelectiveprocedure,
and the risk for developing decreased kidney function
was 3-fold greater following a nonelective procedure.
Recently published guidelines for the surveillance
and monitoring of renal angiomyolipomas suggest a
monitoring frequency of every 1 to 3 years throughout
the patient’s lifetime; however, the age at which
monitoring should begin is not well deﬁned.23 Find-
ings from this study estimate 8.6 years to be the median
age of initial angiomyolipoma detection, consistent
with ﬁndings from other studies.4,24,25 Consequently,
initiating monitoring no later than the age of 10 years
would help ensure early detection.
As noted, the 5.4 years of follow-up in which radio-
logic imaging was available proved too short to broadly
observe angiomyolipoma stage progression. However,
based on a median age of 8.6 years at ﬁrst detectable
angiomyolipoma (stage 1) and a median age of 46.0
years for becoming high risk (stage $ 3), the average
timebetween stages couldbe estimated at approximately
13 years (38.4 years for 3 transitions), assuming linear
progression. It is important to note that there is age
dependence to this observation and due to the exclusion
of patients younger than 18 years, progression in chil-
dren and adolescents has yet to be determined. Unfor-
tunately, this study was unable to add insight into
whether angiomyolipomas grow de novo in adults with
TSC. When new-onset angiomyolipomas were docu-
mented, it was difﬁcult to ascertain whether they
appeared de novo or were previously present but unde-
tectable. Similarly, in patients requiring repeat emboli-
zation, it was not captured whether those subsequent
embolizations were on the same or new lesions.
Consistent with the ﬁndings reported by Shepherd
et al10 in 1991, kidney disease was the leading cause of
death in patients with TSC in the current study despite
the substantial advances in detection, monitoring, and
treatment of angiomyolipomas, including elective
embolization. Both studies also reported increasedAm J Kidney Dis. 2015;66(4):638-645
Renal Angiomyolipoma in the Netherlandsmortality rates in patients with TSC compared with the
general population in their respective countries.
The risk for mortality was signiﬁcantly higher in
patients with low or very low cognitive function, in-
dependent of the highest angiomyolipoma stage. In-
tellectual disability in patients with TSC, often
associated with communication challenges and behav-
ioral issues, can prove to be a barrier to diagnosis and
optimal care.Additionally, inmany cases, the guardians
of these patients object to the more aggressive treat-
ments, such as hemodialysis or peritoneal dialysis.
Renal angiomyolipoma associated with TSC clearly
results in substantial morbidity and mortality. Proactive
surveillance and monitoring of patients, beginning no
later than the age of 10 years and continuing throughout
life with increasing frequency with advancing age, are
recommended for all patients with TSC.23 Early
detection and treatment are essential for the prevention
of progressive damage to renal tissue and ultimately for
improving patient outcomes. There is a high need for
additional treatment options for patients with TSC.
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